Tornado Therapeutics, Inc.

Annual Awards Program Recognizes Innovation in the Global Life Sciences and Biotechnology Industry NEW YORK , Nov. 4, 2022 /PRNewswire/ -- Cambrian BioPharma, a multi-asset longevity biotech, today announced that its CEO, James Peyer, has been selected as "BioTech Company CEO of the Year" in the second annual BioTech Breakthrough Awards, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products and services around the globe. James Peyer, Ph.D., is CEO and Founder of Cambrian Biopharma, which is bridging the gap between academic discovery and drug development, under their Distributed Development Company (or DisCo) model. The company uniquely provides in-house drug discovery capabilities, such as the identification of promising breakthrough science, deep due diligence, deployment of capital and teams of drug development experts. Peyer has implemented three unique key factors in Cambrian's operations: Offering a diversification of drugs in development under the Cambrian PipeCo umbrella, Economies of scale that have resulted in a cash efficiency of 30 to 50% better than other biotechs operating in the field, and Touting a high chance of pushing drugs past initial safety and efficacy hurdles to invest in clinical platforms for preventative medicines. Since 2019, Peyer's Cambrian has grown from three drugs more than a dozen therapeutics that are currently in development. These drugs specifically target damage that occurs at the cellular, subcellular, and tissue levels of the body. This past year, Cambrian Biopharma closed an oversubscribed $100 million Series C to advance healthspan-boosting therapeutics to the clinic and advance the company's existing pipeline. Most recently, Cambrian launched Oviva Therapeutics, a PipeCo specifically aiming to develop novel therapeutics that will extend the healthspan in women by targeting ovarian function and longevity. Cambrian also announced a licensing agreement to advance and develop selective mTOR inhibitors under their subsidiary Tornado Therapeutics. "Thank you so much to BioTech Breakthrough for honoring me and the work of my entire team in this way. Our 'Secret Master Plan' consists of three stages: get approval for newly developed geroprotectors as treatments for existing diseases, conduct large trials to show that these medicines slow aging in at-risk people and, finally, use the huge amounts of data we've gathered to approve geroprotectors that will help people in good health stay that way," said James Peyer, CEO, Cambrian BioPharma. "My goal is to continue to strategically analyze the healthcare landscape and address the unmet needs of the global population, creating medicines that keep people healthy instead of treating symptoms reactively. Most recently, in tandem with Tornado, I'm determined to develop safer, more effective mTOR inhibitors to extend human healthspan." The mission of the annual BioTech Breakthrough Awards program is to conduct the industry's most comprehensive analysis and evaluation of the top companies, solutions and products in the life sciences and biotechnology industry today. This year's program attracted more than 1,350 nominations from over 12 different countries throughout the world. "The last decade has seen our understanding of how and why we age expand dramatically. People everywhere should be able to live healthier, longer. The development of geroprotectors (i.e. drugs that prevent age-related decline) accounts for just a tiny fraction of research dollars," said Bryan Vaughn, Managing Director of BioTech Breakthrough Awards. "James Peyer's Cambrian is breaking through the BioTech market with his mission to create new medicines that target the drivers of aging and increase the period of life spent in good health. Their business model combines the advantages of a venture capital firm and a big pharmaceutical company, with the nimbleness of a biotech startup. Congratulations to James Peyer on winning 'BioTech Company CEO of the Year' for 2022." About Cambrian BioPharma Cambrian BioPharma is building the medicines that will redefine healthcare in the 21st century – therapeutics to lengthen healthspan, the period of life spent in good health. As a Distributed Development Company, Cambrian is advancing multiple scientific breakthroughs each targeting a biological driver of aging. Its approach is to develop interventions that treat specific diseases first, then deploy them as preventative medicines to improve overall quality of life during aging. To date, Cambrian has more than a dozen novel therapeutics in development across its pipeline. For more information, please visit or follow us on Twitter @CambrianBio and LinkedIn. About BioTech Breakthrough Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the BioTech Breakthrough Awards program is devoted to honoring excellence in life science and biotechnology solutions, services and companies. The BioTech Breakthrough Awards provide public recognition for the achievements of biotechnology companies and products in categories including BioPharma, Genomics, Therapeutics, Food Science and BioAgriculture, and more. For more information visit BioTechBreakthroughawards.com Media Contact: Rosa Argyropoulos Senior Director, Global Corporate Communications, Cambrian BioPharma [email protected] SOURCE Cambrian Biopharma

NewYork, New York, September 14, 2022 - Cambrian BioPharma, a multi-asset longevity biotech, today announces its Scientific Advisory Board (SAB) and appointment of C. David Nicholson, PhD and Frank S. Walsh, PhD to lead. The SAB is an independent, external group that provides strategic guidance to the company and regularly reviews its R&D pipeline with the aim to objectively assess and validate the progress made for various pipeline companies. The SAB was formed in October 2021 and meets biannually to review the strategy, plans and progress of projects in the R&D pipeline. As an independent entity, the board adds value by providing an objective external perspective and constructively challenges the strategy, plans and execution of each program. SAB reports are shared with individual pipeline companies for consideration in project strategy and planning and are also shared with the Cambrian BioPharma Board of Directors. Moving forward Cambrian may add further SAB members or ad-hoc advisors as its pipeline grows and matures. “Cambrian BioPharma is honored to have two highly experienced R&D executives to assist with our pursuit of expanding healthspan in the 21st century,” said Brenton L. Saunders, Cambrian BioPharma Board of Director. “Their insight and knowledge will help us to propel our pipeline companies and R&D forward and ensure that we are headed on a path to success.” C.David Nicholson, PhD is currently the non-executive chairman of the board of directors at Exscientia, a lead independent director at Actinium Pharmaceuticals and an operational partner at Gilde Healthcare. Formerly, David was EVP and Chief R&D Officer at Allergan (2014-2020), Chief Technology Officer and EVP at Bayer Crop Science (2012-2014), SVP Licensing and Knowledge Management at Merck (2009-2011), SVP Global Project Management and Drug Safety at Schering-Plough (2007-2009), and EVP R&D at Organon (2006-2007), a company he joined in 1988. He received his PhD in 1980 from University of Wales and his BSc from University of Manchester. C. David Nicholson shared: “I am excited to be a member of the Cambrian SAB. Healthy aging is an aspiration for us all, and advancements in science make this goal increasingly achievable. l am delighted to be able to provide guidance to the teams at Cambrian developing agents to enhance health as we age.” Frank S.Walsh, PhD is the CEO of Ossianix, a privately held protein engineering biotech company that he founded for the development of biological therapeutics using single-domain VNAR antibody technology. Formerly, Frank was SVP/EVP and Head of Discovery Research worldwide at Wyeth Pharmaceuticals in Collegeville (2002-2009). Prior to joining Wyeth, he was SVP at GlaxoSmithKline and Head of the Neurology CEDD (2000-2002), and VP ofNeuroscience Research at Smith Kline Beecham (1997-2000). Before joining the pharmaceutical industry, Frank had a distinguished academic career in Neuroscience as the Sir William Dunn Professor of Experimental Pathology at London’s UMDS, Guy’s Hospital. Frank received his PhD in 1977 from University College London and his BSc from the University of Strathclyde in Glasgow. He is the author of over 200 scientific publications and is a Fellow of the Royal Society of Edinburgh and the UK Academy of Medical Sciences. Frank S. Walsh shared: “Cambrian has identified and invested in a number of companies that have exciting and innovative programs in the area of longevity. The problem is extremely important to all of us and there are now glimmers of progress. I look forward to assisting Cambrian in turning these assets into therapeutics with huge medical and commercial potential.” The announcement of the SAB comes on the heels of a number of exciting pipeline companies coming out of Cambrian BioPharma such as Oviva Therapeutics and Tornado Therapeutics. Cambrian BioPharma has an exciting roadmap planned – to learn more visit https://www.cambrianbio.com/pipeline About Cambrian BioPharma Cambrian BioPharma is building the medicines that will redefine healthcare in the 21st century – therapeutics to lengthen healthspan, the period of life spent in good health. As a Distributed Development Company, Cambrian is advancing multiple scientific breakthroughs each targeting a biological driver of aging. Its approach is to develop interventions that treat specific diseases first, then deploy them as preventative medicines to improve overall quality of life during aging. To date, Cambrian has more than a dozen novel therapeutics in development across its pipeline. For more information, please visit www.cambrianbio.com or follow us on Twitter @CambrianBio and LinkedIn. Contact‍ Rosa Argyropoulos Senior Director, Global Corporate Communications, Cambrian BioPharma rosa@cambrianbio.com